Lonza Group said on Monday that China’s Junshi Biosciences has licensed the Swiss contract drug manufacturer’s technology to help produce a neutralizing antibody against COVID-19.

Lonza said Junshi’s first neutralizing antibody against the new coronavirus was created using the Swiss company’s gene expression system, called GS Xceed.

The antibody, JS016, has entered clinical trials in China, with the first healthy volunteer dosed on June 8 in an early-stage safety study. Source: Reuters 13/7/2020